INSIGHTS ON FACILITY DESIGN
-
![IMG_7470-feature]( "Overcoming Cell Line Development Challenges Through CDMO Outsourcing")
Overcoming Cell Line Development Challenges Through CDMO OutsourcingSuccessful cell line development demands the right microbial strain or mammalian cell line for the application, efficient production processes, and a CDMO capable of shepherding the biologic through technical and regulatory barriers.
-
![Northway-Biotechpharma LABS 66 (3)]( "Optimizing CDMO Tech Transfer")
Optimizing CDMO Tech TransferMany of the logistical, cost, and technical challenges associated with tech transfers can be overcome when the transfer takes place under one roof or occurs between near-identical facilities.
-
![1]( "Northway Biotech Expands To The US: Boston Facility Grand Opening")
Northway Biotech Expands To The US: Boston Facility Grand OpeningMany biologics developers utilize CDMOs to augment their existing supply or for development and manufacturing needs, but choosing the right outsourcing partner can be overwhelming.
-
![science drug development data iStock-1209661917]( "Effectively Managing Data In Process Development")
Effectively Managing Data In Process DevelopmentAddressing data management challenges during drug development requires an understanding of today’s shortcomings and the factors to consider when adopting a solution to overcome them.
-
Covid-19 Impact On Bioprocessing: PART 3 Long-Term Changes
Although suppliers have proven themselves rather robust in their dealing with the pandemic and business is continuing generally uninterrupted, there will be significant long-term changes.
-
Re-Imagining Vaccine Manufacturing To Address Global Health Challenges
In the last decade, biopharmaceutical industries have mobilized quickly in response to pandemics. Developing vaccines and manufacturing large doses in response to an emergency is often constrained by existing platforms and facility configurations. Learn how vaccine manufacturing can evolve to tackle future global health challenges.
-
COVID-19 Impact On Bioprocessing: PART 1 Accelerating Trends
Because of the urgent demand for treatments, vaccines and assays, the pharmaceutical and biotech industries are experiencing disruptive, often chaotic, increased demands on resources.
-
Three Options To Viral Vector Manufacturing Capacity
A recent Virtual Think Tank focused on the challenges and trends influencing design considerations for viral vector manufacturing facilities, and how they can impact companies developing cell and gene therapies.
-
What You Need To Know Before Investing In A Bioprocessing Space
Selecting the bioreactor that is best for your process and the dedicated space you have available requires consideration of many important factors.
FACILITY DESIGN SOLUTIONS
-
Super Plant 4
To fulfill the increasing demand of life-saving solutions for patients' lives all over the world, we decided to drive forward with building our new facility, Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence, becoming your future biomanufacturing hub.
-
Ibex® Dedicate
As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.
-
GE Life Sciences Overview - Cell Processing
Helping your cell therapies succeed through our reach and resources.
-
![genderless-aseptiquik-l-series-connectors]( "Genderless AseptiQuik® L Series Connectors")
Genderless AseptiQuik® L Series ConnectorsGenderless AseptiQuik® Large Format 3/4", 1" and 1½" sanitary Connectors enable quick and easy sterile connections, even in non-sterile environments. The easy-to-use genderless design simplifies system integration and minimizes the risk of operator error. The connector's robust construction provides enhanced user confidence and reliable performance without the need for clamps, fixtures or tube welders. Biopharmaceutical manufacturers benefit from a full range of interchangeable 3/4" to 1½" flow solutions for production environments with the quality and market availability they expect from the leader in single-use connection technology.
-
Transformations In Biomanufacturing
In biomanufacturing the only certainty is risk and the only constant is change. Technology is pushing new frontiers, new markets are opening up across the globe, and new competition is creating new levels of urgency—all under the ever more watchful eye of regulators.
